CL2019003095A1 - Anticuerpos anti-cd33 y métodos para utilizarlos. - Google Patents
Anticuerpos anti-cd33 y métodos para utilizarlos.Info
- Publication number
- CL2019003095A1 CL2019003095A1 CL2019003095A CL2019003095A CL2019003095A1 CL 2019003095 A1 CL2019003095 A1 CL 2019003095A1 CL 2019003095 A CL2019003095 A CL 2019003095A CL 2019003095 A CL2019003095 A CL 2019003095A CL 2019003095 A1 CL2019003095 A1 CL 2019003095A1
- Authority
- CL
- Chile
- Prior art keywords
- antibodies
- compositions
- methods
- enhanced
- project33
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
LA PRESENTE DESCRIPCIÓN. HACE REFERENCIA, EN LÍNEAS GENERALES, A COMPOSICIONES QUE INCLUYEN ANTICUERPOS, POR EJEMPLO, ANTICUERPOS MONOCLONALES, QUIMÉRICOS, HUMANIZADOS, FRAGMENTOS DE ANTICUERPOS, ETC., QUE SE UNEN ESPECÍFICAMENTE A UNO O MÁS EPÍTOPOS DE UNA PROTEÍNA CD33, POR EJEMPLO, CD33 HUMANA O CD33 DE MAMÍFERO Y TIENEN CARACTERÍSTICAS FUNCIONALES MEJORADAS Y/O POTENCIADAS, Y AL USO DE DICHAS COMPOSICIONES PARA PREVENIR, REDUCIR EL RIESGO Y TRATAR A UN INDIVIDUO QUE LO NECESITE.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762541024P | 2017-08-03 | 2017-08-03 | |
US201862667388P | 2018-05-04 | 2018-05-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2019003095A1 true CL2019003095A1 (es) | 2020-02-21 |
Family
ID=63245104
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2019003095A CL2019003095A1 (es) | 2017-08-03 | 2019-10-28 | Anticuerpos anti-cd33 y métodos para utilizarlos. |
CL2020001619A CL2020001619A1 (es) | 2017-08-03 | 2020-06-16 | Anticuerpos anti-cd33 y métodos para utilizarlos. (divisional solicitud 201903095) |
CL2021003535A CL2021003535A1 (es) | 2017-08-03 | 2021-12-28 | Anticuerpos anti-cd33 y métodos para utilizarlos. (divisional de solicitud 3095-2019) |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2020001619A CL2020001619A1 (es) | 2017-08-03 | 2020-06-16 | Anticuerpos anti-cd33 y métodos para utilizarlos. (divisional solicitud 201903095) |
CL2021003535A CL2021003535A1 (es) | 2017-08-03 | 2021-12-28 | Anticuerpos anti-cd33 y métodos para utilizarlos. (divisional de solicitud 3095-2019) |
Country Status (19)
Country | Link |
---|---|
US (3) | US10711062B2 (es) |
EP (1) | EP3589658A1 (es) |
JP (2) | JP7299160B2 (es) |
KR (1) | KR20200033798A (es) |
CN (2) | CN117700548A (es) |
AU (1) | AU2018310985A1 (es) |
BR (1) | BR112019023789A2 (es) |
CA (1) | CA3057447A1 (es) |
CL (3) | CL2019003095A1 (es) |
CO (1) | CO2019012200A2 (es) |
CR (1) | CR20190486A (es) |
EC (1) | ECSP19078414A (es) |
IL (3) | IL270238B (es) |
MA (1) | MA47691A (es) |
PE (1) | PE20200486A1 (es) |
PH (1) | PH12019502463A1 (es) |
TW (1) | TW201920268A (es) |
WO (1) | WO2019028283A1 (es) |
ZA (1) | ZA201906366B (es) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11466082B2 (en) | 2018-05-24 | 2022-10-11 | Janssen Biotech, Inc. | Anti-CD33 antibodies, anti-CD33/anti-CD3 bispecific antibodies and uses thereof |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7376977B2 (ja) | 2015-06-12 | 2023-11-09 | アレクトル エルエルシー | 抗cd33抗体及びその使用方法 |
EP3307779A2 (en) | 2015-06-12 | 2018-04-18 | Alector LLC | Anti-cd33 antibodies and methods of use thereof |
US20230121869A1 (en) * | 2016-03-04 | 2023-04-20 | Alector Llc | Anti-TREM1 Antibodies and Methods of Use Thereof |
JOP20190248A1 (ar) | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
CN117700548A (zh) | 2017-08-03 | 2024-03-15 | 艾利妥 | 抗cd33抗体及其使用方法 |
ES2952982T3 (es) | 2017-08-03 | 2023-11-07 | Alector Llc | Anticuerpos anti-TREM2 y métodos de uso de los mismos |
WO2020068058A1 (en) * | 2018-09-25 | 2020-04-02 | Academia Sinica | Anti-siglec antibody, pharmaceutical composition comprising the same, and uses thereof |
WO2020239947A1 (en) * | 2019-05-29 | 2020-12-03 | Centre National De La Recherche Scientifique | Prognosis method of leukemia |
AU2020403021A1 (en) * | 2019-12-12 | 2022-06-23 | Alector Llc | Methods of use of anti-CD33 antibodies |
WO2023081898A1 (en) | 2021-11-08 | 2023-05-11 | Alector Llc | Soluble cd33 as a biomarker for anti-cd33 efficacy |
WO2023114499A1 (en) | 2021-12-17 | 2023-06-22 | Denali Therapeutics Inc. | Polypeptide engineering, libraries, and engineered cd98 heavy chain and transferrin receptor binding polypeptides |
CN117447594A (zh) * | 2022-07-26 | 2024-01-26 | 北京东方百泰生物科技股份有限公司 | 一种抗Siglec-15单克隆抗体 |
CN116375874B (zh) * | 2023-04-14 | 2023-12-26 | 上海精翰生物科技有限公司 | 一种cd33抗体及其应用 |
Family Cites Families (125)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
US4469863A (en) | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
CA1338518C (en) | 1987-09-23 | 1996-08-13 | Joyce M. Zarling | Antibody heteroconjugates for the killing of hiv-infected cells |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
KR0184860B1 (ko) | 1988-11-11 | 1999-04-01 | 메디칼 리써어치 카운실 | 단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법) |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
DE69029036T2 (de) | 1989-06-29 | 1997-05-22 | Medarex Inc | Bispezifische reagenzien für die aids-therapie |
US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
DE69033631T2 (de) | 1989-12-14 | 2001-05-17 | Sloan Kettering Inst Cancer | Therapeutische verwendungen der hypervariablen region des monoklonalen antikörpers m195 und konstrukte davon |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5321131A (en) | 1990-03-08 | 1994-06-14 | Hybridon, Inc. | Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling |
US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
JPH06500011A (ja) | 1990-06-29 | 1994-01-06 | ラージ スケール バイオロジー コーポレイション | 形質転換された微生物によるメラニンの製造 |
ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
ES2113940T3 (es) | 1990-12-03 | 1998-05-16 | Genentech Inc | Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas. |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
EP0586505A1 (en) | 1991-05-14 | 1994-03-16 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
DK51092D0 (da) | 1991-05-24 | 1992-04-15 | Ole Buchardt | Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf |
US5719262A (en) | 1993-11-22 | 1998-02-17 | Buchardt, Deceased; Ole | Peptide nucleic acids having amino acid side chains |
ES2206447T3 (es) | 1991-06-14 | 2004-05-16 | Genentech, Inc. | Anticuerpo humanizado para heregulina. |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
US7018809B1 (en) | 1991-09-19 | 2006-03-28 | Genentech, Inc. | Expression of functional antibody fragments |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
JPH07501451A (ja) | 1991-11-25 | 1995-02-16 | エンゾン・インコーポレイテッド | 多価抗原結合タンパク質 |
ES2202310T3 (es) | 1991-12-13 | 2004-04-01 | Xoma Corporation | Metodos y materiales para la preparacion de dominios variables de anticuerpos modificados y sus usos terapeuticos. |
US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
US5700922A (en) | 1991-12-24 | 1997-12-23 | Isis Pharmaceuticals, Inc. | PNA-DNA-PNA chimeric macromolecules |
AU675929B2 (en) | 1992-02-06 | 1997-02-27 | Curis, Inc. | Biosynthetic binding protein for cancer marker |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
ZA932523B (en) | 1992-04-10 | 1994-10-08 | Res Dev Foundation | Immunotoxins directed against cd33 related surface antigens |
RU95104940A (ru) | 1992-07-27 | 1997-01-10 | Хайбрайдон | Способ введения в олигонуклеотид алкилфосфонотиоатной или арилфосфонотиоатной межнуклеотидной связи, способ получения олигонуклеотида, олигонуклеотиды, способ ингибирования генной экспрессии, способ лечения |
ATE149570T1 (de) | 1992-08-17 | 1997-03-15 | Genentech Inc | Bispezifische immunoadhesine |
EP0680489A1 (en) | 1993-01-21 | 1995-11-08 | HYBRIDON, Inc. | Foldback triplex-forming oligonucleotides |
US5637684A (en) | 1994-02-23 | 1997-06-10 | Isis Pharmaceuticals, Inc. | Phosphoramidate and phosphorothioamidate oligomeric compounds |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
ES2304786T3 (es) | 1995-04-27 | 2008-10-16 | Amgen Fremont Inc. | Anticuerpos anti-il-8 humanos, derivados a partir de xenoratones inmunizados. |
EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
US5962674A (en) | 1995-06-01 | 1999-10-05 | Hybridon, Inc. | Synthesis of oligonucleotides containing alkylphosphonate internucleoside linkages |
US5955599A (en) | 1995-06-01 | 1999-09-21 | Hybridon, Inc. | Process for making oligonucleotides containing o- and s- methylphosphotriester internucleoside linkages |
US6140482A (en) | 1995-06-01 | 2000-10-31 | Hybridon, Inc. | Primary phosphoramidate internucleoside linkages and oligonucleotides containing the same |
US5614622A (en) | 1995-06-01 | 1997-03-25 | Hybridon, Inc. | 5-pentenoyl moiety as a nucleoside-amino protecting group, 4-pentenoyl-protected nucleotide synthons, and related oligonucleotide syntheses |
US5637683A (en) | 1995-07-13 | 1997-06-10 | Cornell Research Foundation, Inc. | Nucleic acid analog with amide linkage and method of making that analog |
US5652356A (en) | 1995-08-17 | 1997-07-29 | Hybridon, Inc. | Inverted chimeric and hybrid oligonucleotides |
AU7378096A (en) | 1995-09-28 | 1997-04-17 | Alexion Pharmaceuticals, Inc. | Porcine cell interaction proteins |
DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
AU4089397A (en) | 1996-08-26 | 1998-03-19 | Hybridon, Inc. | Improved reagents and process for synthesis of oligonucleotides containing phosphorodithioate internucleoside linkages |
US5886165A (en) | 1996-09-24 | 1999-03-23 | Hybridon, Inc. | Mixed backbone antisense oligonucleotides containing 2'-5'-ribonucleotide- and 3'-5'-deoxyribonucleotides segments |
DK1500329T3 (da) | 1996-12-03 | 2012-07-09 | Amgen Fremont Inc | Humane antistoffer, der specifikt binder TNF-alfa |
US5739314A (en) | 1997-04-25 | 1998-04-14 | Hybridon, Inc. | Method for synthesizing 2'-O-substituted pyrimidine nucleosides |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
ATE531812T1 (de) | 1997-12-05 | 2011-11-15 | Scripps Research Inst | Humanisierung von nager-antikörpern |
US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
ATE332909T1 (de) | 1999-03-24 | 2006-08-15 | Exiqon As | Verbesserte synthese für 2.2.1.öbicyclo- nukleoside |
KR20010001577A (ko) | 1999-06-07 | 2001-01-05 | 윤종용 | 고분자 광산발생제를 이용한 올리고펩티드 핵산 탐침의 제조방법 |
AU6629200A (en) | 1999-08-25 | 2001-03-19 | Philip P Garner | Alpha-helical peptide nucleic acid alpha-pna |
AU782626B2 (en) | 1999-10-04 | 2005-08-18 | Medicago Inc. | Method for regulating transcription of foreign genes |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
WO2001029058A1 (en) | 1999-10-15 | 2001-04-26 | University Of Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
JP3523245B1 (ja) | 2000-11-30 | 2004-04-26 | メダレックス,インコーポレーテッド | ヒト抗体作製用トランスジェニック染色体導入齧歯動物 |
US6455308B1 (en) | 2001-08-01 | 2002-09-24 | Isis Pharmaceuticals, Inc. | Antisense modulation of serum amyloid A4 expression |
US20030206916A1 (en) | 2002-05-03 | 2003-11-06 | Rush-Presbyterian-St. Luke's Medical Center | Immunogenic peptides |
US20040119010A1 (en) | 2002-11-01 | 2004-06-24 | The Regents Of The University Of Colorado | Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry |
MXPA05004712A (es) | 2002-11-07 | 2005-11-23 | Immunogen Inc | Anticuerpos anti-cd33 y metodo para tratamiento de leucemia mieloide aguda utilizando los mismos. |
MXPA06011199A (es) | 2004-03-31 | 2007-04-16 | Genentech Inc | Anticuerpos anti-tgf-beta humanizados. |
JP2008526205A (ja) | 2004-12-31 | 2008-07-24 | ジェネンテック・インコーポレーテッド | Br3に結合するポリペプチド及びその使用 |
EP1851245B1 (en) | 2005-01-26 | 2012-10-10 | Amgen Fremont Inc. | Antibodies against interleukin-1 beta |
US7700099B2 (en) | 2005-02-14 | 2010-04-20 | Merck & Co., Inc. | Non-immunostimulatory antibody and compositions containing the same |
TW200726776A (en) | 2005-07-29 | 2007-07-16 | Friedrich Alexander University Of Erlangen Nuremberg | CD33-specific single-chain immunotoxin and methods of use |
US7420040B2 (en) | 2006-02-24 | 2008-09-02 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
EP4316465A3 (en) | 2006-03-15 | 2024-04-24 | Alexion Pharmaceuticals, Inc. | Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement |
CA2651567A1 (en) | 2006-05-09 | 2007-11-22 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
JP2010509234A (ja) | 2006-11-02 | 2010-03-25 | シアトル ジェネティックス, インコーポレイテッド | 新生物疾患、自己免疫疾患および炎症性疾患を処置する方法 |
US8465741B2 (en) * | 2006-12-20 | 2013-06-18 | Mmrglobal, Inc. | Antibodies and methods for making and using them |
UY30776A1 (es) | 2006-12-21 | 2008-07-03 | Medarex Inc | Anticuerpos cd44 |
CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
EP2193146B1 (en) | 2007-09-14 | 2016-05-25 | Adimab, LLC | Rationally designed, synthetic antibody libraries and uses therefor |
FR2945538B1 (fr) | 2009-05-12 | 2014-12-26 | Sanofi Aventis | Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide. |
US9885711B2 (en) | 2009-09-25 | 2018-02-06 | Xoma Technology Ltd. | Screening methods |
DE102009045006A1 (de) | 2009-09-25 | 2011-04-14 | Technische Universität Dresden | Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen |
EP2560994B1 (en) * | 2010-04-08 | 2016-10-12 | JN Biosciences LLC | Antibodies to cd122 |
EP4219805A1 (en) | 2010-07-16 | 2023-08-02 | Adimab, LLC | Antibody libraries |
UA112062C2 (uk) * | 2010-10-04 | 2016-07-25 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Cd33-зв'язувальний агент |
WO2012074097A1 (ja) * | 2010-12-03 | 2012-06-07 | 協和発酵キリン株式会社 | 抗cd33抗体 |
US20130309223A1 (en) * | 2012-05-18 | 2013-11-21 | Seattle Genetics, Inc. | CD33 Antibodies And Use Of Same To Treat Cancer |
CN102952191B (zh) | 2012-09-17 | 2014-05-14 | 浙江大学 | 全人源抗cd33单链抗体zjl101及其应用 |
BR112015015289A2 (pt) * | 2012-12-24 | 2017-08-15 | Abbvie Inc | Proteínas que se ligam ao receptor de prolactina e usos das mesmas |
US9937231B2 (en) | 2013-03-27 | 2018-04-10 | The General Hospital Corporation | Methods and agents for treating Alzheimer's disease |
SG10201710013RA (en) * | 2013-08-13 | 2018-01-30 | Sanofi Sa | Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof |
MA39095A1 (fr) | 2013-12-13 | 2018-08-31 | Genentech Inc | Anticorps et immunoconjugués anti-cd33 |
AR101669A1 (es) | 2014-07-31 | 2017-01-04 | Amgen Res (Munich) Gmbh | Constructos de anticuerpos para cdh19 y cd3 |
US10501555B2 (en) | 2014-12-04 | 2019-12-10 | Abruzzo Theranostic S.R.L. | Humanized anti-trop-2 monoclonal antibodies and uses thereof |
EP3307779A2 (en) | 2015-06-12 | 2018-04-18 | Alector LLC | Anti-cd33 antibodies and methods of use thereof |
JP7376977B2 (ja) | 2015-06-12 | 2023-11-09 | アレクトル エルエルシー | 抗cd33抗体及びその使用方法 |
US9914781B1 (en) * | 2016-11-08 | 2018-03-13 | Glaxosmithkline Intellectual Property Development Limited | Binding agonist for treatment of neurological and other disorders |
CN117700548A (zh) | 2017-08-03 | 2024-03-15 | 艾利妥 | 抗cd33抗体及其使用方法 |
EP3843851A1 (en) | 2018-08-31 | 2021-07-07 | Alector LLC | Anti-cd33 antibodies and methods of use thereof |
-
2018
- 2018-08-02 CN CN202311258379.1A patent/CN117700548A/zh active Pending
- 2018-08-02 WO PCT/US2018/045056 patent/WO2019028283A1/en active Application Filing
- 2018-08-02 JP JP2019559021A patent/JP7299160B2/ja active Active
- 2018-08-02 MA MA047691A patent/MA47691A/fr unknown
- 2018-08-02 CN CN201880027790.9A patent/CN110662765B/zh active Active
- 2018-08-02 KR KR1020197035734A patent/KR20200033798A/ko not_active Application Discontinuation
- 2018-08-02 PE PE2019002182A patent/PE20200486A1/es unknown
- 2018-08-02 CA CA3057447A patent/CA3057447A1/en active Pending
- 2018-08-02 EP EP18756115.4A patent/EP3589658A1/en active Pending
- 2018-08-02 AU AU2018310985A patent/AU2018310985A1/en active Pending
- 2018-08-02 BR BR112019023789-5A patent/BR112019023789A2/pt unknown
- 2018-08-02 CR CR20190486A patent/CR20190486A/es unknown
- 2018-08-03 US US16/054,840 patent/US10711062B2/en active Active
- 2018-08-03 TW TW107127182A patent/TW201920268A/zh unknown
-
2019
- 2019-09-26 ZA ZA2019/06366A patent/ZA201906366B/en unknown
- 2019-10-28 IL IL270238A patent/IL270238B/en unknown
- 2019-10-28 CL CL2019003095A patent/CL2019003095A1/es unknown
- 2019-10-30 CO CONC2019/0012200A patent/CO2019012200A2/es unknown
- 2019-10-31 PH PH12019502463A patent/PH12019502463A1/en unknown
- 2019-10-31 EC ECSENADI201978414A patent/ECSP19078414A/es unknown
-
2020
- 2020-05-07 US US16/869,315 patent/US11254743B2/en active Active
- 2020-06-16 CL CL2020001619A patent/CL2020001619A1/es unknown
-
2021
- 2021-12-28 CL CL2021003535A patent/CL2021003535A1/es unknown
-
2022
- 2022-01-16 IL IL289882A patent/IL289882A/en unknown
- 2022-01-16 IL IL289880A patent/IL289880A/en unknown
- 2022-01-21 US US17/581,471 patent/US20220162309A1/en active Pending
-
2023
- 2023-06-15 JP JP2023098189A patent/JP2023134445A/ja active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11466082B2 (en) | 2018-05-24 | 2022-10-11 | Janssen Biotech, Inc. | Anti-CD33 antibodies, anti-CD33/anti-CD3 bispecific antibodies and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
TW201920268A (zh) | 2019-06-01 |
CA3057447A1 (en) | 2019-02-07 |
IL289882A (en) | 2022-03-01 |
AU2018310985A1 (en) | 2019-11-07 |
CL2021003535A1 (es) | 2022-08-19 |
MA47691A (fr) | 2020-01-08 |
CO2019012200A2 (es) | 2020-04-01 |
KR20200033798A (ko) | 2020-03-30 |
CR20190486A (es) | 2020-02-10 |
US10711062B2 (en) | 2020-07-14 |
EP3589658A1 (en) | 2020-01-08 |
US20220162309A1 (en) | 2022-05-26 |
CN117700548A (zh) | 2024-03-15 |
JP2020532947A (ja) | 2020-11-19 |
JP2023134445A (ja) | 2023-09-27 |
US20190040131A1 (en) | 2019-02-07 |
JP7299160B2 (ja) | 2023-06-27 |
PH12019502463A1 (en) | 2020-06-15 |
PE20200486A1 (es) | 2020-03-03 |
CL2020001619A1 (es) | 2020-09-25 |
CN110662765A (zh) | 2020-01-07 |
ZA201906366B (en) | 2021-02-24 |
WO2019028283A1 (en) | 2019-02-07 |
CN110662765B (zh) | 2023-09-29 |
US11254743B2 (en) | 2022-02-22 |
US20210139581A1 (en) | 2021-05-13 |
ECSP19078414A (es) | 2019-12-27 |
IL270238B (en) | 2022-02-01 |
IL289880A (en) | 2022-03-01 |
BR112019023789A2 (pt) | 2020-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2019003095A1 (es) | Anticuerpos anti-cd33 y métodos para utilizarlos. | |
CL2019003093A1 (es) | Anticuerpos anti-trem2 y métodos para utilizarlos. | |
ECSP20024555A (es) | Anticuerpos especificos para cd47 y pd-l1 | |
CL2020001575A1 (es) | Anticuerpos anti-trem2 y métodos relacionados. | |
ECSP19072235A (es) | Anticuerpos anti-ILT4 y fragmentos de unión a antígeno | |
CL2018000744A1 (es) | Anticuerpos anti-tigit (inmunoreceptor de linfocitos t con dominios ig e itim) y metodos de uso. | |
CL2017002401A1 (es) | Anticuerpos contra icos | |
ECSP17083779A (es) | Agentes de unión a inmunorreceptor de células t con dominios ig y motivo de inhibición basado en tirosina de inmunorreceptor (tigit) y usos de los mismos | |
CO2017012553A2 (es) | Moléculas de unión a lag-3 | |
CR20170383A (es) | Anticuerpos anti-cd3, anticuerpos anti-cd-123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123 | |
CO2017006740A2 (es) | Anticuerpos anti–cd79b | |
CO2018011195A2 (es) | Composiciones que comprenden una coformulación de anticuerpos anti-pd-l1 y anti-ctla-4 | |
CL2017000250A1 (es) | Anticuerpo monoclonal anti-ctla4 o su fragmento de unión a antígeno, una composición farmacéutica y uso | |
BR112017003582A2 (pt) | anticorpos, composições e usos | |
CR20170096A (es) | Tratamientos conjuntos con anticuerpos anti cd40 | |
BR112017022838A2 (pt) | receptores quiméricos de antígeno de antígenos de mieloma kappa e seus usos | |
AR100680A1 (es) | Anticuerpos anti-dr5 y moléculas que comprenden dominios de unión de dr5 de los mismos | |
CL2017002983A1 (es) | Terapia combinada de un anticuerpo anti-cd-20 con un inhibidor de bcl-2 y un inhibidor de mdm2 | |
CO2018003852A2 (es) | Proteínas de unión a antigeno que activan el receptor de leptina | |
BR112019001206A2 (pt) | anticorpos monoclonais humanizados que visam ve-ptp (hptp-ss) | |
CO2019011640A2 (es) | Métodos y composiciones para la reducción de la inmunogenicidad | |
ECSP21022299A (es) | Anticuerpos de anti-cd33 y métodos para usarlos | |
CO2020006453A2 (es) | Anticuerpos anti-cxcr5 y composiciones y usos de los mismos | |
CL2018000303A1 (es) | Combinaciones de proteínas de unión antigénicas anti-ox40 con un modulador de tlr4 y sus usos | |
BR112017022073A2 (pt) | método para purificação de proteína |